Breast cancer therapy

Breast cancer therapy has been studied in 2 papers since 2023: 1 observational study in people, 1 review; 1 in the past year. The newest story, Nov 19, 2026: “Treatment-induced menopause linked to lasting vaginal changes”.

Exposure

2 papers study it3 findingsUpdated

1 new paper in 30 daysSee all 2 papers on breast cancer therapy

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“Within three months of menopause onset, participants exhibited significant deterioration in vulvovaginal health”
Breast cancer therapy-induced menopause rapidly and persistently disrupts vaginal health and microbial ecologyResearch Square2026doi:10.21203/rs.3.rs-11570017/v1

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Humans1

What is breast cancer therapy linked with?

3

Studies link breast cancer therapy with 3 measures: vaginal microbiome composition, sexual dysfunction and vulvovaginal health.

Vaginal microbiome composition

mixedin humans1

1 study
  1. Breast cancer therapy is associated with vaginal microbiome composition in humans (Iatrogenic menopause; more pronounced changes in endocrine therapy recipients).

    HumansIatrogenic menopause; more pronounced changes in endocrine therapy recipientsvaginaUp to 33 monthsfemalesn = 60

    Treatment-induced menopause linked to lasting vaginal changes

    Research SquarePreprint

More on Vaginal microbiome composition

Sexual dysfunction

upin humans1

1 study
  1. Breast cancer therapy is associated with sexual dysfunction in humans (Iatrogenic menopause; particularly among endocrine therapy recipients).

    HumansIatrogenic menopause; particularly among endocrine therapy recipientsWithin three months of menopause onsetfemalesn = 60

    Treatment-induced menopause linked to lasting vaginal changes

    Research SquarePreprint

More on Sexual dysfunction

Vulvovaginal health

downin humans1

1 study
  1. Breast cancer therapy is associated with vulvovaginal health in humans (Premenopausal women with stage I–IIIC breast cancer undergoing iatrogenic menopause).

    HumansPremenopausal women with stage I–IIIC breast cancer undergoing iatrogenic menopausevulva and vaginaWithin three months of menopause onsetfemalesn = 60

    Treatment-induced menopause linked to lasting vaginal changes

    Research SquarePreprint

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months
Research Square

Treatment-induced menopause linked to lasting vaginal changes

Vaginal health worsened within three months of menopause onset in women receiving breast cancer therapy; bacterial shifts persisted for up to 33 months.Vaginal health worsened within three months of menopause onset in women receiving breast cancer therapy; bacterial shifts persisted for up to 33 months.

Preprint: cohort · 60 peopleGenitourinary syndrome of menopause